$EKSO
EKSO BIONICS HOLDINGS, INC.

2021 Q4 Form 10-Q Financial Statement

#000154908421000044 Filed on November 02, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $4.076M $3.049M $2.897M
YoY Change 81.16% 5.25% -12.71%
Cost Of Revenue $1.661M $1.242M $1.084M
YoY Change 86.63% 14.58% -30.91%
Gross Profit $2.415M $1.807M $1.813M
YoY Change 77.57% -0.33% 3.6%
Gross Profit Margin 59.25% 59.27% 62.58%
Selling, General & Admin $6.149M $3.978M $3.446M
YoY Change 68.47% 15.44% -21.52%
% of Gross Profit 254.62% 220.14% 190.07%
Research & Development $818.0K $618.0K $599.0K
YoY Change 15.21% 3.17% -47.87%
% of Gross Profit 33.87% 34.2% 33.04%
Depreciation & Amortization $130.0K $158.0K $150.0K
YoY Change -13.33% 5.33% 400.0%
% of Gross Profit 5.38% 8.74% 8.27%
Operating Expenses $6.967M $4.596M $4.234M
YoY Change 59.79% 8.55% -23.57%
Operating Profit -$4.552M -$2.789M -$2.421M
YoY Change 51.73% 15.2% -36.12%
Interest Expense -$236.0K $24.00K $23.00K
YoY Change 686.67% 4.35% -73.86%
% of Operating Profit
Other Income/Expense, Net $1.925M $831.0K $4.873M
YoY Change -302.63% -82.95% 21.95%
Pretax Income -$2.863M -$1.958M $2.450M
YoY Change -28.07% -179.92% 1066.67%
Income Tax
% Of Pretax Income
Net Earnings -$2.863M -$1.958M $2.452M
YoY Change -28.07% -179.85% 1090.29%
Net Earnings / Revenue -70.24% -64.22% 84.64%
Basic Earnings Per Share -$0.15 $0.30
Diluted Earnings Per Share -$225.7K -$0.17 -$0.01
COMMON SHARES
Basic Shares Outstanding 12.66M shares 12.66M shares 8.236M shares
Diluted Shares Outstanding 12.71M shares 8.379M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.41M $43.44M $14.55M
YoY Change 214.2% 198.55% 80.52%
Cash & Equivalents $40.41M $43.44M $14.55M
Short-Term Investments
Other Short-Term Assets $485.0K $788.0K $370.0K
YoY Change 155.26% 112.97% -13.95%
Inventory $2.242M $1.751M $2.180M
Prepaid Expenses
Receivables $4.662M $3.121M $4.450M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $47.80M $49.10M $21.55M
YoY Change 159.47% 127.85% 26.51%
LONG-TERM ASSETS
Property, Plant & Equipment $991.0K $1.172M $1.033M
YoY Change -15.44% 13.46% -40.05%
Goodwill $0.00 $0.00
YoY Change -100.0%
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $164.0K $125.0K $118.0K
YoY Change -48.75% 5.93% -31.4%
Total Long-Term Assets $1.371M $1.634M $1.937M
YoY Change -37.02% -15.64% -40.55%
TOTAL ASSETS
Total Short-Term Assets $47.80M $49.10M $21.55M
Total Long-Term Assets $1.371M $1.634M $1.937M
Total Assets $49.17M $50.73M $23.49M
YoY Change 138.7% 116.01% 15.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.107M $1.308M $1.813M
YoY Change 107.0% -27.85% 33.11%
Accrued Expenses $2.299M $1.704M $1.566M
YoY Change 60.88% 8.81% -39.51%
Deferred Revenue $1.220M $1.291M $1.448M
YoY Change -18.45% -10.84% 3.58%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.855M $4.675M $5.233M
YoY Change 37.82% -10.66% -35.29%
LONG-TERM LIABILITIES
Long-Term Debt $1.993M $1.992M $3.080M
YoY Change 0.2% -35.32% 216.87%
Other Long-Term Liabilities $74.00K $54.00K $30.00K
YoY Change 94.74% 80.0% 76.47%
Total Long-Term Liabilities $2.067M $2.046M $30.00K
YoY Change 1.97% 6720.0% -96.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.855M $4.675M $5.233M
Total Long-Term Liabilities $2.067M $2.046M $30.00K
Total Liabilities $11.95M $11.67M $15.09M
YoY Change -26.08% -22.63% 8.75%
SHAREHOLDERS EQUITY
Retained Earnings -$208.9M -$206.0M -$195.1M
YoY Change 4.9% 5.57% 8.07%
Common Stock $13.00K $13.00K $8.000K
YoY Change 62.5% 62.5% -89.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.22M $39.06M $8.401M
YoY Change
Total Liabilities & Shareholders Equity $49.17M $50.73M $23.49M
YoY Change 138.7% 116.01% 15.74%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$2.863M -$1.958M $2.452M
YoY Change -28.07% -179.85% 1090.29%
Depreciation, Depletion And Amortization $130.0K $158.0K $150.0K
YoY Change -13.33% 5.33% 400.0%
Cash From Operating Activities -$3.075M -$2.475M -$1.270M
YoY Change 76.72% 94.88% -72.21%
INVESTING ACTIVITIES
Capital Expenditures $1.000K -$60.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $1.000K -$60.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 2.540M
YoY Change -100.0% -523.33%
NET CHANGE
Cash From Operating Activities -3.075M -2.475M -1.270M
Cash From Investing Activities 1.000K -60.00K 0.000
Cash From Financing Activities 0.000 0.000 2.540M
Net Change In Cash -3.074M -2.535M 1.270M
YoY Change 76.67% -299.61% -124.56%
FREE CASH FLOW
Cash From Operating Activities -$3.075M -$2.475M -$1.270M
Capital Expenditures $1.000K -$60.00K $0.00
Free Cash Flow -$3.076M -$2.415M -$1.270M
YoY Change 76.78% 90.16% -72.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001549084
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.06667
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37854
dei Entity Registrant Name
EntityRegistrantName
Ekso Bionics Holdings, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0367049
dei Entity Address Address Line1
EntityAddressAddressLine1
1414 Harbour Way South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1201
dei Entity Address City Or Town
EntityAddressCityOrTown
Richmond
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94804
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
984-1761
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
EKSO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3224000 USD
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12663717 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43439000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12862000 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
42000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3121000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
1751000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
788000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
356000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
49099000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18420000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1172000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1172000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
337000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
685000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000 USD
CY2021Q3 us-gaap Assets
Assets
50733000 USD
CY2020Q4 us-gaap Assets
Assets
20597000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1308000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1501000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1704000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1291000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
372000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
548000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4675000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4974000 USD
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1449000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
1992000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3075000 USD
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
3501000 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6037000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
54000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
271000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
11671000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
16163000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12664000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12664000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8349000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8349000 shares
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1242000 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
13000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
245299000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
204376000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-246000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-847000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206004000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199103000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
39062000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50733000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3049000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2897000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7170000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6628000 USD
CY2021Q3 us-gaap Gross Profit
GrossProfit
1807000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
1813000 USD
us-gaap Gross Profit
GrossProfit
4334000 USD
us-gaap Gross Profit
GrossProfit
3709000 USD
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1685000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1084000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2836000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2919000 USD
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1740000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5265000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5972000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
618000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
599000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1930000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1762000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2293000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1706000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6415000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5836000 USD
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2020Q3 us-gaap Restructuring Charges
RestructuringCharges
0 USD
us-gaap Restructuring Charges
RestructuringCharges
0 USD
us-gaap Restructuring Charges
RestructuringCharges
244000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
4596000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
4234000 USD
us-gaap Operating Expenses
OperatingExpenses
13610000 USD
us-gaap Operating Expenses
OperatingExpenses
14003000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2789000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2421000 USD
us-gaap Interest Expense
InterestExpense
113000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9276000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10294000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
24000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
23000 USD
us-gaap Interest Expense
InterestExpense
77000 USD
CY2021Q3 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
1125000 USD
CY2020Q3 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
4476000 USD
ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
2011000 USD
ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-1579000 USD
CY2021Q3 ekso Warrant Issuance Expense
WarrantIssuanceExpense
0 USD
CY2020Q3 ekso Warrant Issuance Expense
WarrantIssuanceExpense
0 USD
ekso Warrant Issuance Expense
WarrantIssuanceExpense
0 USD
ekso Warrant Issuance Expense
WarrantIssuanceExpense
329000 USD
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1099000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q3 ekso Other Income Expense
OtherIncomeExpense
-270000 USD
CY2020Q3 ekso Other Income Expense
OtherIncomeExpense
420000 USD
ekso Other Income Expense
OtherIncomeExpense
-658000 USD
ekso Other Income Expense
OtherIncomeExpense
466000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
831000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4873000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2375000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1555000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1958000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2452000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6901000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11849000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
261000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-415000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
601000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-435000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1697000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2037000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6300000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12284000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.75
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12661000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8236000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12029000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6772000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12710000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8379000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12133000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6829000 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3670000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35360000 USD
CY2021Q1 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
3878000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
152000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
356000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
465000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
40975000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1273000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
519000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-125000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
40096000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1958000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
663000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
261000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
39062000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6797000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2534000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
155000 USD
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
50000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
587000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
173000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5228000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11767000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7082000 USD
CY2020Q2 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1436000 USD
CY2020Q2 ekso Adjustments To Additional Paid In Capital Warrant Issuance
AdjustmentsToAdditionalPaidInCapitalWarrantIssuance
2322000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
508000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-193000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-28000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2452000 USD
CY2020Q3 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
5875000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
517000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-415000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
8401000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6901000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11849000 USD
us-gaap Depreciation
Depreciation
431000 USD
us-gaap Depreciation
Depreciation
465000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
48000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
43000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1099000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
2011000 USD
ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-1579000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
329000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1538000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1612000 USD
ekso Common Stock Contribution
CommonStockContribution
141000 USD
ekso Common Stock Contribution
CommonStockContribution
155000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-55000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-640000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
424000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-715000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
171000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-469000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-97000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-70000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-169000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-189000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-90000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-409000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-528000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-23000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8081000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7015000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37295000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7082000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1278000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1512000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3078000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1417000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3334000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38712000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10704000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-12000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30577000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3677000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12862000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10872000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43439000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14549000 USD
us-gaap Interest Paid Net
InterestPaidNet
69000 USD
us-gaap Interest Paid Net
InterestPaidNet
86000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
6000 USD
ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
1936000 USD
ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
0 USD
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2461000 USD
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
0 USD
ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
387000 USD
ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
-160000 USD
ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
152000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
50000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206004000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8081000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43439000 USD
CY2021Q3 ekso Debt Covenant Covenant Compliance Unrestricted Cash
DebtCovenantCovenantComplianceUnrestrictedCash
2000000 USD
ekso Unrestricted Cash
UnrestrictedCash
41439000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of September 30, 2021 and December 31, 2020. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the Company had no customers with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable, as compared with two customers at December 31, 2020 (10% and 13%).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, the Company had no customers with sales of 10% or more of the Company’s total revenue, as compared with one customer in the three months ended September 30, 2020 (13%).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021 and 2020, the Company had no customers with sales of 10% or more of the Company’s total revenues.</span></div>
ekso Number Of Customers
NumberOfCustomers
0 customer
CY2020 ekso Number Of Customers
NumberOfCustomers
2 customer
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
601000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-435000 USD
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1442000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1724000 USD
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
177000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
18000 USD
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
132000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
236000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
1751000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2021Q3 ekso Contract With Customer Liability Extended Maintenance And Support
ContractWithCustomerLiabilityExtendedMaintenanceAndSupport
2387000 USD
CY2020Q4 ekso Contract With Customer Liability Extended Maintenance And Support
ContractWithCustomerLiabilityExtendedMaintenanceAndSupport
2902000 USD
CY2021Q3 ekso Contract With Customer Liability Royalties
ContractWithCustomerLiabilityRoyalties
280000 USD
CY2020Q4 ekso Contract With Customer Liability Royalties
ContractWithCustomerLiabilityRoyalties
282000 USD
CY2021Q3 ekso Contract With Customer Liability Devices And Advances
ContractWithCustomerLiabilityDevicesAndAdvances
73000 USD
CY2020Q4 ekso Contract With Customer Liability Devices And Advances
ContractWithCustomerLiabilityDevicesAndAdvances
118000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2740000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1291000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1449000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
ekso Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
799000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1361000 USD
CY2021Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2740000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2740000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
443000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1055000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1242000 USD
CY2021Q3 ekso Contractwith Customer Liability Non Cancellable Backlog
ContractwithCustomerLiabilityNonCancellableBacklog
1103000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3049000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7170000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2897000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6628000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1515000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1194000 USD
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
157000 USD
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
188000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
47000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1704000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43439000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2000000 USD
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
8000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
1992000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1992000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
1992000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
150000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
234000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
384000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
372000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y8M8D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
130000 USD
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
132000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
395000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
405000 USD
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12664000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12664000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8349000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8349000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
141000 USD
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
155000 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1325000 shares
ekso Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
273000 shares
ekso Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
358000 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1240000 shares
ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1417000 USD
ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1436000 USD
ekso Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
358000 shares
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
663000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
517000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1538000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1612000 USD
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
34000 USD
CY2020Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
56000 USD
CY2021Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
50000 USD
CY2021Q3 us-gaap Contractual Obligation
ContractualObligation
2697000 USD
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
396000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1958000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2452000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6901000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11849000 USD
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
158000 USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2545000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
643000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
294000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2116000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-93000 USD
CY2021Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
49000 shares
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7544000 USD
CY2020Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
143000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
104000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
57000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12710000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6772000 shares
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12143000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12661000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8236000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12029000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8379000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12133000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6829000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.75
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1976000 shares
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2142000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1427000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1946000 shares
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3049000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1242000 USD
CY2021Q3 us-gaap Gross Profit
GrossProfit
1807000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2897000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1084000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
1813000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7170000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2836000 USD
us-gaap Gross Profit
GrossProfit
4334000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6628000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2919000 USD
us-gaap Gross Profit
GrossProfit
3709000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3049000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2897000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7170000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6628000 USD

Files In Submission

Name View Source Status
0001549084-21-000044-index-headers.html Edgar Link pending
0001549084-21-000044-index.html Edgar Link pending
0001549084-21-000044.txt Edgar Link pending
0001549084-21-000044-xbrl.zip Edgar Link pending
ekso-20210930.htm Edgar Link pending
ekso-20210930.xsd Edgar Link pending
ekso-20210930_cal.xml Edgar Link unprocessable
ekso-20210930_def.xml Edgar Link unprocessable
ekso-20210930_htm.xml Edgar Link completed
ekso-20210930_lab.xml Edgar Link unprocessable
ekso-20210930_pre.xml Edgar Link unprocessable
ekso-9302021xex311.htm Edgar Link pending
ekso-9302021xex312.htm Edgar Link pending
ekso-9302021xex321.htm Edgar Link pending
ekso-9302021xex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending